Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00867087 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: inotuzumab ozogamicin (CMC-544)
DRUG: rituximab

Sponsor

Pfizer

Collaborators

[object Object]